Karyopharm Therapeutics

KPTI

Market cap $194M

Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Karyopharm Therapeutics faces heightened uncertainty after mixed phase 3 SENTRY results for selinexor in myelofibrosis. KPTI met the spleen volume reduction endpoint but missed symptom improvement, while showing a promising, though immature, overall survival signal. Dire cash position persists despite a $30 million private placement; runway extends only into Q2 2026, with existential funding risks looming.

Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis, raising questions on efficacy.

Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares are down on Tuesday as the company reported mixed results from its Phase 3 SENTRY trial for myelofibrosis.

Karyopharm Therapeutics said ​on Tuesday its ‌oncology therapy showed a ​statistically ​significant improvement in spleen ⁠volume ​in a late‑stage ​trial in patients with a ​rare blood ​cancer, one of ‌the ⁠study's main goals.

NEWTON, Mass., March 24, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with RA Capital Management for a private placement that is expected to result in gross proceeds of approximately $30 million before deducting placement agent fees and offering expenses, and an additional approximately $44 million of gross proceeds if the accompanying warrants are exercised in full.

– While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS – – SENTRY Demonstrated a Rapid and Near Doubling of Patients Achieving SVR35 at Week 24, versus Ruxolitinib – – Promising Overall Survival Signal with >50% Reduction of Risk of Death versus Ruxolitinib – – Evidence of Potential Disease Modification with More Patients Achieving ≥20% Reductions in VAF as Early as Week 24 versus Ruxolitinib – – No New Safety Signals Identified – – Karyopharm will Meet with the FDA to Discuss the Totality of the Data and Potential sNDA Filing – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass.

NEWTON, Mass., March 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,450 restricted stock units (RSUs) to two newly-hired employees.

The consensus price target hints at a 56.1% upside potential for Karyopharm Therapeutics (KPTI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.